Jobbet "PhD fellowship: the AIM (ABL-class Imatinib pharmacokinetics/-dynamics Monitoring) study" er udløbet

Region Hovedstaden

Region Hovedstaden

Blegdamsvej 9, 2100 København Ø

Dit næste skridt

 

A position for a 3-year full-time position as PhD student (research assistant; expected start: Fall 2021) is available at Rigshospitalet for a highly motivated and independent MD with interest in hematology/oncology and pharmacology.

The job: We offer an exciting job in an international environment with the possibility of working at the interface of pre-clinical/laboratory-based activities and clinical activities at pediatric/adult clinical departments of hemato-oncology.

This project focuses on personalized medicine in the setting of tyrosine kinase inhibitor therapy, a flagship for molecularly targeted therapy in cancer used for a large and still expanding group of hematological cancers in both children and adults, the BCR-ABL1-positive/-like leukemias. How can we tailor the treatment to reduce toxicities (increase quality of life) and improve efficacy (cure rate) for each patient?

You will be involved in

- systematic review methodology and meta-analysis within the Cochrane collaboration exploring the utility of therapeutic drug monitoring of tyrosine kinase inhibitors

- laboratory-based activities including mapping of pharmacokinetics/-dynamics of tyrosine kinase inhibitors in a clinical practice setting in close collaboration with the clinical departments (aim: improve improve efficacy/cure rates and reduce toxicity/increase quality of life)

- targeted cytogenetic profiling exploring underlying mechanisms for treatment resistance/failure

Duration:: We offer a full-time position (start can be negotiated) including preparation (1 month) for a 3-year contract position as a PhD student (est. start in Fall 2021).

For additional information please contact Cecilie Utke Rank, MD, PhD, Tel: +45 2685 8297 / E-mail: cecilie.utke.rank@regionh.dk

Work place: The multi-institutional research is coordinated by the Department of Pediatrics and Adolescent Medicine, Rigshospitalet; the Department of Hematology, Rigshospitalet; and the Department of Clinical Pharmacology, Bispebjerg and Frederiksberg University Hospital.

The PhD student’s workplace will be at the Pediatric Oncology Research Laboratory (Bonkolab), Rigshospitalet. Bonkolab bridges preclinical and clinical work housing staff for (1) biochemical analyses (2 senior researchers; 1 coordinating laboratory technician, 8 full-time lab technicians, 8 clinical trial nurses); (2) biostatistics; (3) bioinformatics as well as (4) >20 PhD students and 8 postdocs (in total 120 employees). Bonkolab is the only site in Denmark that has established and runs pharmacokinetic analysis of tyrosine kinase inhibitors and the laboratory is coordinating the Danish Cancer Society Research Centre CONTROL (Childhood Oncology Network Targeting Research, Organization & Life expectancy).

PhD supervisors:

- Kjeld Schmiegelow, MD, DMSc, professor; Department of Pediatrics and Adolescent Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

- Christen Lykkegaard Andersen, MD, PhD, DMSc, professor; Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

- Cecilie Utke Rank, MD, PhD; Department of Hematology, Rigshospitalet, University of Copenhagen,

- Kim Peder Dalhoff, MD, DMSc, professor; Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark

Collaborators of the project:

Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital. Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital. Proteomics Program CPR, Olsen Group, Faculty of Health and Medical Sciences, University of Copenhagen. Biotech Research & Innovation Centre (BRIC), University of Copenhagen.

Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen University Hospital. Department of Pediatric Hematology and Oncology, Odense University Hospital. Children and Adolescent Health, Aarhus University Hospital. Department of Pediatric Cancer and Blood Disorders, Oslo University Hospital.

Department of Hematology, Rigshospitalet, Copenhagen University Hospital. Department of Hematology, Zealand University Hospital, Roskilde. Department of Hematology, Odense University Hospital. Department of Hematology, Aarhus University Hospital. Department of Hematology, Oslo University Hospital.

Requirements & qualifications:

- MD with successfully completed KBU

- Work experience in clinical hematology/oncology

- Excellent written and spoken English communication skills

- Some research experience and publications in peer-reviewed journals

- High level of motivation and able to work independently

- Structured approach to documentation and data management

Salary and terms of employment: Salary and terms of employment follow current Danish agreements and regulation for similar positions.

Application: The application should include the following items:

• A cover letter (max 1 page) describing your background, personal qualities, research interests and specific reasons for applying for this position.

• Curriculum vitae (max 3 pages).

• List of peer reviewed publications. You may include manuscripts that have been accepted for publication or are in review.

• Transcripts of Diplomas (Master’s degree or equivalent).

• References: Please include contact details for two persons willing to provide you with a reference. Briefly state your personal relationship with them. Reference persons will only be contacted, if you are among the final candidates being considered for the position.

The chosen candidate will be requested to formally apply for enrolment as a PhD student at the PhD school of Health and Medical Sciences, University of Copenhagen.

The application should be written in English and submitted electronically.

Deadline: May 7, 2021 (23:59 CET) A few selected candidates will be invited for a personal interview in Week 19 at Rigshospitalet. The personal interview will be conducted in Danish.